Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 9 Triple Negative Breast Neoplasms 5 Stomach Neoplasms 2 Neoplasm Metastasis 2 Uterine Cervical Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Lung Neoplasms 1 Liver Neoplasms 1 HER2-negative Breast Cancer 1 Gastric Adenocarcinoma 1 Gallbladder Neoplasms 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

eribulin 3 Vinorelbine 2 Paclitaxel 2 Epirubicin 2 Doxorubicin 2 Cyclophosphamide 2 trastuzumab deruxtecan 1 tislelizumab 1 taxane 1 sacituzumab govitecan 1 pembrolizumab 1 liposomal doxorubicin 1 camrelizumab 1 anlotinib 1 Taxes 1 Precision Medicine 1 Gemcitabine 1 Docetaxel 1 Cisplatin 1 Carboplatin 1 Capecitabine 1 Anthracyclines 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HER2-negative Breast Cancer × taxane × Clear all

NCT06102824 2024-11-25

ORIENTA

Guangdong Provincial People's Hospital

Phase 2 Recruiting

HER2-negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡